PARP Inhibitors for Ovarian Cancer

Clinical Pearls

Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, discusses PARP inhibitors for the treatment of ovarian cancer.

• In breast cancer, maintenance drugs exist to keep patients in remission following chemotherapy. There remains a need for such agents in ovarian cancer.
• Though only 10-15% of patients harbor a BRCA1/2 mutation, they may see benefit from treatment with a PARP inhibitor.